Article

DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen

University of Southampton School of Medicine, Southampton General Hospital, Southampton, UK.
European Journal of Immunology (Impact Factor: 4.52). 08/2011; 41(8):2447-56. DOI: 10.1002/eji.201141518
Source: PubMed

ABSTRACT For long-term attack on tumor cells in patients with prostate cancer, induction of cytolytic T cells is desirable. Several lineage-specific target proteins are known and algorithms have identified candidate MHC class I-binding peptides, particularly for HLA-A*0201. We have designed tolerance-breaking DNA fusion vaccines incorporating a domain of tetanus toxin fused to candidate tumor-derived peptide sequences. Using three separate peptide sequences from prostate-specific membrane antigen (PSMA) (peptides PSMA(27) , PSMA(663) , and PSMA(711) ), this vaccine design induced high levels of CD8(+) T cells against each peptide in a HLA-A(*) 0201 preclinical model. In contrast, the full-length PSMA sequence containing all three epitopes was poorly immunogenic. Induced T cells were cytotoxic against peptide-loaded tumor cells, but only those against PSMA(27) or PSMA(663) peptides, and not PSMA(711) , were able to kill tumor cells expressing endogenous PSMA. Cytotoxicity was also evident in vivo. The preclinical model provides a powerful tool for generating CD8(+) T cells able to predict whether target cells can process and present peptides, essential for planning peptide vaccine-based clinical trials.

Full-text

Available from: Christian Ottensmeier, Oct 01, 2014
0 Followers
 · 
88 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Self-tolerance, presumably through lineage-unbiased elimination of self antigen-specific lymphocytes (CD4+ T, CD8+ T and B cells), creates a formidable barrier to cancer immunotherapy. In contrast to this prevailing paradigm, we demonstrate that for some antigens self-tolerance reflects selective elimination of antigen-specific CD4+ T cells, but preservation of CD8+ T- and B-cell populations. In mice, antigen-specific CD4+ T-cell tolerance restricted CD8+ T- and B-cell responses targeting the endogenous self antigen guanylyl cyclase c (GUCY2C) in colorectal cancer. While selective CD4+ T-cell tolerance blocked GUCY2C-specific antitumor immunity and memory responses, it offered a unique solution to the inefficacy of GUCY2C vaccines through recruitment of self antigen-independent CD4+ T-cell help. Incorporating CD4+ T-cell epitopes from foreign antigens into vaccines against GUCY2C reconstituted CD4+ T-cell help, revealing the latent functional capacity of GUCY2C-specific CD8+ T- and B-cell pools, producing durable antitumor immunity without autoimmunity. Incorporating CD4+ T-cell epitopes from foreign antigens into vaccines targeting self antigens in melanoma (Trp2) and breast cancer (Her2) produced similar results, suggesting selective CD4+ T-cell tolerance underlies ineffective vaccination against many cancer antigens. Thus, identification of self antigens characterized by selective CD4+ T-cell tolerance and abrogation of such tolerance through self antigen-independent T-cell help is essential for future immunotherapeutics.This article is protected by copyright. All rights reserved
    European Journal of Immunology 07/2014; 44(7). DOI:10.1002/eji.201444539 · 4.52 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The development of vaccines that target tumor antigens in cancer has proven difficult. A major reason for this is that T cells specific for tumor self-antigens and neoantigens are eliminated or inactivated through mechanisms of tolerance. Antigen fusion strategies which increase the ability of vaccines to stimulate T cells that have escaped tolerance mechanisms, may have a particular potential as immunotherapies. This review highlights antigen fusion strategies that have been successful in stimulating the induction of T-cell immunity against cancer and counteracting tumor-associated tolerance. In preclinical studies, these strategies have shown to improve the potency of vectored vaccines through fusion of tumor antigen to proteins or protein domains that increase CD4+ T-cell help, CD8+ T-cell responses or both the CD4+ and CD8+ T-cell responses. However, in clinical trials such strategies seem to be less efficient when provided as a DNA vaccine. The first clinical trial using a viral vectored fusion-gene vaccine is expected to be tested as a partner in a heterologous prime-boost regimen directed against cervical cancer.
    05/2013; 1(1):33-47. DOI:10.1177/2051013613480446
  • [Show abstract] [Hide abstract]
    ABSTRACT: Delivery of plasmid DNA encoding an antigen of interest has been demonstrated to be an effective means of immunization, capable of eliciting antigen-specific T cells. Plasmid DNA vaccines offer advantages over other anti-tumor vaccine approaches in terms of simplicity, manufacturing, and possibly safety. The primary disadvantage is their poor transfection efficiency and subsequent lower immunogenicity relative to other genetic vaccine approaches. However, multiple preclinical models demonstrate anti-tumor efficacy, and many efforts are underway to improve the immunogenicity and anti-tumor effect of these vaccines. Clinical trials using DNA vaccines as treatments for prostate cancer have begun, and to date have demonstrated safety and immunological effect. This review will focus on DNA vaccines as a specific means of antigen delivery, advantages and disadvantages of this type of immunization, previous experience in preclinical models and human trials specifically conducted for the treatment of prostate cancer, and future directions for the application of DNA vaccines to prostate cancer immunotherapy.
    Current Cancer Therapy Reviews 11/2012; 8(4):254-263. DOI:10.2174/157339412804143113